SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (2152)3/26/1999 1:51:00 PM
From: AJAG  Respond to of 10280
 
Morgan Stanley Dean Witter reiterated its strong buy rating today, stock price target 165. Looks like a bit of " buy on the rumor, sell on the news" has hit us. It will pass.



To: Biomaven who wrote (2152)3/26/1999 1:59:00 PM
From: Bob Swift  Respond to of 10280
 
Peter,
I didn't know that 1/4 of the dose of xopenex is just as effective. I use to think it was 1/2 the dose. If so, it definitely means the S-isomer is harmful. It would be criminal for physicians to prescribe the Racemic Albuterol. I hope the salesmen get that point across effectively. May be one of the patients can file a lawsuit to get the physicians' attention. Any voluteer ?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News